WHO GAP-f network outlines paediatric medicines priorities on World Children's Day
The World Health Organization's Global Accelerator for Paediatric Formulations Network published an update on 20 November 2026 reaffirming its 2025-2030 roadmap and 30 by '30 targets across 10 diseases, 10 medicines and 10 countries, alongside a new South-East Asia pilot report.
Event / data period:
Published: · Updated:

The World Health Organization and partners in the Global Accelerator for Paediatric Formulations Network, known as GAP-f, issued an update on 20 November 2026 to mark World Children's Day and review ongoing work to expand access to safe, effective and age-appropriate medicines for children. Hosted by WHO, the network brings together institutions across industry, academia, civil society and global health agencies. While noting progress in clinical research and formulation development, the update stressed that significant gaps persist in turning scientific advances into treatments that reach children in all settings.
Central to the network's multi-year work is the GAP-f Strategic Roadmap 2025-2030, anchored by a measurable framework called the 30 by '30 commitment. Under that commitment, GAP-f and its partners aim by 2030 to assess priorities across 10 high-burden diseases, accelerate the development and availability of 10 priority paediatric medicines and strengthen national paediatric medicines ecosystems in 10 countries. The update reaffirmed these three targets as shared benchmarks requiring sustained funding, regulatory coordination and country-level follow-through rather than isolated research projects.
Sylvie Briand, WHO chief scientist and acting assistant director-general for health systems, access and data, underscored the urgency of closing delays in child-focused drug development. She stated that children should not have to wait for medicines designed for their specific clinical needs, adding that aligning global priorities, strengthening paediatric clinical research and helping countries translate innovation into practical access are essential to achieving equitable health outcomes for every child.
The first operational pillar highlighted in the 20 November 2026 update centers on prioritization through WHO's Paediatric Drug Optimization process, known as PADO. Through PADO, GAP-f convenes technical experts and partner organizations to identify priority medicines and child-friendly formulations that address critical gaps in disease prevention and treatment. The network also pointed to a dedicated GAP-f product portfolio designed to consolidate these priorities into a single reference so that academic researchers, pharmaceutical developers and global health funders can concentrate resources on the highest-impact paediatric needs.
The second pillar focuses on generating stronger clinical evidence for children, who have historically been underrepresented in drug trials. GAP-f reported that it is working with partners to map global clinical research site capacity, promote the inclusion of children in clinical studies and encourage more efficient trial designs. To operationalize this effort, the network is assembling a package of clinical research resources combining information on global paediatric clinical trial sites, training materials on trial design and implementation, and cross-stakeholder recommendations on optimal study methodologies.
The third pillar addresses the transition from product development to country-level availability and clinical uptake. Developing an age-appropriate formulation does not guarantee that clinics and families can obtain or afford it without functioning regulatory pathways, procurement systems and national treatment guidelines. GAP-f stated that it works alongside WHO technical departments, Member States and partner organizations to diagnose bottlenecks in country access and support the practical introduction of optimal paediatric formulations.
As a concrete example of regional implementation, WHO highlighted a workshop convened in May 2026 with GAP-f partners in the South-East Asia region focused on strengthening paediatric medicines ecosystems. The gathering brought together national stakeholders from four pilot countries to examine structural barriers and identify workable solutions. Accompanying the World Children's Day update, a new report from the May 2026 workshop documents those findings and outlines practical opportunities for countries to align global prioritization and clinical evidence with local health-system realities.
The update framed paediatric medicines access as a lifecycle challenge spanning early prioritization, clinical trial execution, formulation engineering, regulatory review, financing and health-system delivery. Because no single institution controls every step of that chain, WHO described GAP-f as a coordination platform meant to keep governments, regulators, researchers, product developers, funders and civil society working toward shared milestones rather than fragmented initiatives.
The 20 November 2026 statement is a policy and program progress update rather than an announcement of a specific new drug approval or financing commitment. Measuring whether the 30 by '30 targets are achieved by 2030 will depend on transparent tracking of which 10 high-burden diseases complete PADO assessments, which 10 priority paediatric formulations reach regulatory clearance and country uptake, and what measurable system improvements materialize in the 10 target countries, beginning with follow-up from the four South-East Asia pilot nations.
Data
Key reported figures
Selected 30 by '30 Strategic Roadmap targets and South-East Asia regional pilot figures reported by WHO GAP-f.
- High-burden diseases targeted for priority assessment by 2030
- 10 areas
- 2030 · Target
- Priority paediatric medicines targeted for acceleration by 2030
- 10 items
- 2030 · Target
- Countries targeted for strengthened paediatric medicines ecosystems by 2030
- 10 countries
- 2030 · Target
- Pilot countries represented at the May 2026 South-East Asia regional workshop
- 4 countries
- 2026-05 · Observed
Methodology
Figures retain the source's stated roadmap horizon, scope and definitions. Targets and observed workshop participation are labeled by basis. No missing value is inferred.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Subject suggested from the title or summary: Healthwww.who.int ↗